NEW HAVEN, Conn., May 5, 2020 – Rallybio LLC, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the hiring of Rachael Alford, PhD to lead the Company’s Chemistry, Manufacturing and Controls (CMC) operations. In this role, Dr. Alford will have responsibility for overseeing the process development, analytical and formulation development, and manufacturing and supply chain of Rallybio’s product candidates.
“We are thrilled to have Rachael join the Rallybio team. Rachael’s CMC expertise in moving molecules from the laboratory to patients is perfectly suited for our portfolio of product candidates,” said Steve Uden, MD, co-founder of Rallybio. “Rachael’s experience will ensure process development and manufacturing are optimized, positioning our product candidates to reach the clinic as quickly as possible.”
Dr. Alford brings more than 15 years of CMC experience to Rallybio. Most recently, she served as Vice President, Global Process Development at Alexion Pharmaceuticals, where she led both biologic and small molecule process development across the lifecycle, analytical and formulation development, device development, tech transfer and clinical tech services. During her tenure at Alexion, Dr. Alford assumed positions of increasing responsibility in Technical Operations, developing expertise across the CMC spectrum. Prior to joining Alexion, Dr. Alford was a postdoctoral research associate in the Department of Molecular Biophysics and Biochemistry at Yale University.
“I’m so pleased to join Rallybio to once again work with this team of industry leaders who are focused on developing transformative therapies for patients with rare diseases,” said Dr. Alford. “I am excited to bring my CMC experience to the Company to advance the portfolio and deliver new medicines to those most in need.”
Dr. Alford has a PhD in biophysical chemistry and a BSc in Chemistry from Imperial College, London.
Rallybio is focused on identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The founders of the company – Martin Mackay, PhD, Stephen Uden, MD, and Jeffrey Fryer, CPA – are seasoned leaders from the biopharma industry with a wide breadth of research, development, and financial experience. Named by FierceBiotech as one of its “Fierce 15” Biotech Companies of 2018, the company was recognized as being among “the most promising private biotech startups”. Rallybio is headquartered in New Haven, Connecticut with an additional location at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com.